Department of Internal Medicine, Faculty of Medicine and University Hospital in Hradec Kralove, Charles University in Prague, Sokolska 581, Hradec Kralove, Czech Republic.
Eur J Endocrinol. 2010 Oct;163(4):645-50. doi: 10.1530/EJE-10-0516. Epub 2010 Aug 3.
Screening of thyroid disorders in pregnancy has been controversial. Recent recommendations favour targeted high-risk case finding, though this approach may miss a significant number of those affected. We aimed to assess the prevalence of accepted high-risk criteria in women with autoimmune thyroiditis and/or hypothyroidism detected from universal screening in an iodine-sufficient population.
In 400 non-selected women in the 9-11th gestational week, thyroid-related tests were performed, and those with abnormalities were offered consultation.
TSH was determined by IRMA, and the upper cut-off value for screening was set at 3.5 mIU/l. For free thyroxine (FT(4)) and thyroperoxidase antibodies (TPO-Ab), RIAs were used, with cut-offs of <10 pmol/l and >50 IU/ml respectively. Endocrinological consultation included Doppler ultrasonography and was aimed to confirm autoimmune thyroiditis and/or hypothyroidism. The prevalence of consensus high-risk criteria was assessed.
Among the 400 women, 65 (16.3%) had ≥1 abnormality: higher TSH was found in 10.3%, lower FT(4) in 2% and positive TPO-Ab in 8.3%. Fifty-one women were examined and followed up. Levo-T(4) treatment was initiated in 49 women for autoimmune thyroiditis (in 42), hypothyroidism (in 34) or both (in 27). Only 22 (45%) of 49 treated women fulfilled ≥1 high-risk criterion: most commonly family history (31%), history of miscarriage or preterm delivery (14%) and personal history (8%).
Over half (55%) of pregnant women with abnormalities suggestive of autoimmune thyroiditis and/or hypothyroidism would be missed if only those with high-risk criteria were examined. A more extensive screening of thyroid autoimmunity and dysfunction seems warranted.
妊娠期间甲状腺疾病的筛查一直存在争议。最近的建议支持针对高危病例的有针对性的发现,但这种方法可能会错过相当数量的受影响者。我们旨在评估在碘充足人群中通过普遍筛查发现的自身免疫性甲状腺炎和/或甲状腺功能减退症的女性中,公认的高危标准的患病率。
在第 9-11 孕周的 400 名非选择妇女中,进行了甲状腺相关检查,对异常者提供咨询。
通过 IRMA 测定 TSH,筛查的上限值设定为 3.5 mIU/L。对于游离甲状腺素(FT(4))和甲状腺过氧化物酶抗体(TPO-Ab),使用 RIA,分别为<10 pmol/L 和>50 IU/ml。内分泌学咨询包括多普勒超声检查,旨在确认自身免疫性甲状腺炎和/或甲状腺功能减退症。评估共识高危标准的患病率。
在 400 名妇女中,有 65 名(16.3%)有≥1 项异常:10.3%的 TSH 升高,2%的 FT(4)降低,8.3%的 TPO-Ab 阳性。对 51 名妇女进行了检查和随访。对 49 名妇女进行了左甲状腺素(T(4))治疗,用于自身免疫性甲状腺炎(42 名)、甲状腺功能减退症(34 名)或两者(27 名)。只有 22 名(45%)接受治疗的妇女符合≥1 项高危标准:最常见的是家族史(31%)、流产或早产史(14%)和个人史(8%)。
如果只检查有高危标准的妇女,将错过一半以上(55%)有自身免疫性甲状腺炎和/或甲状腺功能减退症可疑异常的孕妇。似乎需要更广泛的筛查甲状腺自身免疫和功能障碍。